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Protein degradation: Go outside and see the proteasome
J. Michael Lord
Newly synthesized proteins that fail to fold or assemble
properly in the endoplasmic reticulum are degraded.
Recent work on several endoplasmic reticulum
membrane proteins has shown that the cytosolic
proteasome plays a role in their degradation. 
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Most membrane and secretory proteins, and proteins
ultimately located in organelles such as the Golgi com-
plex, endosomes or lysosomes, are synthesized on ribo-
somes that attach to the endoplasmic reticulum (ER)
membrane during translation. During their synthesis,
these proteins are either inserted into the ER membrane
in the correct orientation or discharged into the ER lumen
before moving to their final location within or outside the
cell. But the ER is much more than simply the site of syn-
thesis of these proteins; its lumen provides an environ-
ment in which the nascent proteins fold, undergo a variety
of post-translational modifications and, when appropriate,
assemble into oligomeric structures. This is generally
described as the ‘quality control’ function of the ER [1].
To do this efficiently and effectively, the ER lumen has a
repertoire of proteins that includes molecular chaperones
and folding and modifying enzymes. Only when a protein
is correctly folded and assembled can it exit the ER for
another destination. 
What happens to proteins that fail to fold correctly, or fail
to assemble into oligomeric complexes within the ER?
They do not simply accumulate and remain in this com-
partment. Rather, they are selectively degraded by a pro-
teolytic system able to differentiate between native and
aberrant conformations [2]. The plasma membrane T-cell
receptor complex provides a good example. It is an
oligomer of at least seven different polypeptides that are
synthesized in different amounts in the ER. The number
of correctly assembled heptameric T-cell receptor com-
plexes formed is limited by the availability of the least
abundant constituent, and only heptameric T-cell recep-
tor complexes are correctly targeted to the cell surface;
partial T-cell receptor complexes and individual subunits
are rapidly destroyed. 
When the a subunit of the T-cell receptor is expressed
alone in transfected fibroblasts, it is core glycosylated and
undergoes normal glycan trimming by ER processing
enzymes, but the oligosaccharide side chain remains sensi-
tive to endo H digestion; the glycoprotein never acquires
the resistance to endo H that is diagnostic of transport to
and modification within the Golgi complex. Furthermore,
the subsequent proteolytic removal of the a subunit is
insensitive to drugs that inhibit proteolysis in lysosomes.
Thus, degradation most likely occurs in a pre-Golgi com-
partment, possibly the ER lumen itself [3]. In addition to
T-cell receptor subunits, several other ER membrane pro-
teins are substrates for degradation, including HMG-CoA
reductase, ribophorin, the asialoglycoprotein receptor and
apolipoprotein B-100 [4]. 
These observations suggest the slightly uncomfortable
notion that the protein folding and quality control machin-
ery co-exist in the ER lumen with a proteolytic system
capable of rapidly degrading newly synthesized proteins.
Recent findings, however, are beginning to challenge the
idea that protein degradation occurs exclusively within the
ER. That incorrectly folded or unassembled proteins
unable to exit the ER by vesicular transport are rapidly
degraded is not in dispute, it is the site of degradation that
is now being questioned. 
The cystic fibrosis transmembrane conductance regulator
(CFTR) is another integral membrane protein subjected
to extensive post-translational degradation. Approximately
75 % of wild-type CFTR and 100 % of the DF508 CFTR
variant found in most cystic fibrosis patients does not
mature beyond the ER and is degraded. Last year, it was
demonstrated that degradation of both wild-type and
mutant CFTR is prevented by inhibitors of the cytosolic
proteasome, and that ubiquitination is required for rapid
degradation [5,6]. Another recent paper [7] has shown
that, in yeast, the ubiquitin–proteasome pathway is
involved in the degradation of Sec61p, an essential com-
ponent of the translocon that delivers nascent proteins
into the ER. 
Are cytosolic proteasomes entirely responsible for degrad-
ing these proteins, or are they an important constituent of a
more complex proteolytic system? The orientation of
CFTR in the ER membrane is such that the bulk of the
protein is exposed to the cytosol and might therefore be
available for proteasome processing without any alteration
in membrane topology. For other membrane proteins, such
as Sec61p, it is conceivable that the ubiquitin–proteasome
pathway initiates degradation and is responsible for degrad-
ing the cytosolically exposed domain. Breakdown interme-
diates, including the lumenal domain of the protein, could
be degraded by a different proteolytic system within the
ER lumen. A recent paper by Wiertz et al. [8], which
describes the degradation of MHC class I heavy chain in
virally-infected cells, has added an interesting new twist to
the emerging story.
The human cytomegalovirus (HCMV) compromises the
normal cellular response to viral infection by dramatically
down-regulating the number of cell-surface MHC class I
molecules, which present viral peptides to cytotoxic T
cells. This down-regulation is achieved by rapid degrada-
tion of newly synthesized MHC class I molecules. The
degradation of MHC class I molecules seen in HCMV-
infected cells also occurs in cells transfected with a gene
from the HCMV unique short region, the US11 gene,
which encodes a small type-I transmembrane glycoprotein
that resides in the ER. Wiertz et al. [8] demonstrated that,
in both types of cell, MHC class I heavy chains disappeared
with a half-life of less than one minute. 
Treating US11+ cells with brefeldin A, which stops vesicu-
lar traffic between the ER and the Golgi complex, had no
effect on the half-life of the MHC class I heavy chains [8].
Proteasome inhibitors, however, significantly decreased
the rate of MHC class I heavy chain disappearance. More-
over, the rapidly degraded MHC class I molecules had a
molecular mass of ~43 kDa and were core glycosylated,
whereas proteasome inhibition led to the transient appear-
ance of an ~40 kDa breakdown intermediate that was not
glycosylated. There was a precursor–product relationship
between the 43 kDa and 40 kDa forms, showing the inter-
mediate form had been deglycosylated; inhibition of N-
glycosylation using tunicamycin did not prevent MHC
class I heavy chain degradation. Deglycosylation was cat-
alyzed by an N-glycanase-type activity, implying that it
may occur in the cytosol. 
Subcellular fractionation studies were performed by dif-
ferential centrifugation of control cells and US11+ cells
treated with a proteasome inhibitor [8]. In both types of
cell, the lumenal ER protein calnexin, the transferrin
receptor and MHC class I light chains (b2-microglobulin)
were all quantitatively recovered in the pelleted fractions,
as was US11p in the US11+ cells. Core-glycosylated MHC
class I heavy chains were also exclusively recovered in the
pelleted fractions from control cells. Strikingly, however,
the 40 kDa deglycosylated intermediate was present in
the supernatant from US11+ cells. 
One possible explanation of these observations is that, in
US11+ cells, newly synthesized MHC class I heavy chains
are somehow dislocated from the ER, exported into the
cytosol, deglycosylated and proteolytically degraded. It
should be emphasized that the fractionation experiment
described above does not prove that the intermediate is in
the cytosol. It could, for example, be in small ER-derived
vesicles that fail to pellet under the conditions of centrifu-
gation used. What is clear, however, is that the intermedi-
ate, in contrast to the normal location of MHC class I
heavy chains, appears in a fraction distinct from the bulk
of the ER, and that within this alternative location it is
susceptible to degradation by the proteasome pathway.
Wiertz et al. [8] speculated that dislocation from the ER
may have occurred either by the US11 protein somehow
interfering with the normal membrane insertion of the
MHC class I heavy chain stop-transfer signal, or by pre-
venting the nascent heavy chains from being ‘pulled’ into
the ER lumen by BiP or another ER resident chaperone.
In either model, MHC class I heavy chains were envis-
aged to enter the cytosol by reverse transport through the
translocon that normally imports nascent polypeptides
into the ER [9] (Fig. 1).
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Figure 1
A model for ER protein export and/or
degradation. Newly synthesized soluble or
membrane proteins are co-translationally
inserted into the ER lumen or membrane. 
(a) Correctly folded proteins and assembled
protein complexes destined for post-ER
locations leave the ER in transport vesicles.
(b) Proteins that fail to fold or assemble into
oligomeric structures correctly may be
exported back across the ER membrane into
the cytosol, where they are degraded by
proteasomes. Alternatively, proteasomes may
degrade only the cytosolic domain of ER
membrane proteins. Lumenal proteins and the
lumenal domain of membrane proteins may be
degraded by an alternative proteolytic system,
perhaps within specialized regions of the ER.
If export from the ER to the cytosol occurs,
the translocon that imports nascent proteins
into the ER (see [9]) may be used in the
reverse direction to export misfolded or
unassembled proteins, or a different protein-
conducting channel may be used.
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A number of alternative explanations clearly remain possi-
ble. The aberrant proteins could aggregate in specialized
regions of the ER, where they might remain membrane
associated and attacked at the cytosolic surface by protea-
somal proteases. Alternatively, this specialized region of
the ER might generate small vesicles containing the pro-
teins that themselves become susceptible to proteasomal
attack. Another possibility is that the proteins are degraded
while still associated with the ER membrane, perhaps still
located in the translocon without requiring reverse trans-
port and release from it. Finally, it is possible that proteins
might be exported from the ER via an uncharacterized ER
membrane protein transporter, perhaps one dedicated to
the export of misfolded or unassembled proteins from the
ER for proteolytic degradation in the cytosol. An ER-asso-
ciated export–degradation pathway may be a feature of all
eukaryotic cells as an essential component of the quality
control mechanism. The limited data available at present
do not, of course, preclude the existence of a proteolytic
system within the ER itself.
ER-associated degradation does not appear to be confined
to transmembrane proteins. In the absence of light chains,
secretory immunoglobulin heavy chains are retained in the
ER lumen through binding to the heavy-chain-binding
protein BiP, and are eventually degraded. A failure of
immunoglobulin M oligomers to polymerize also results in
degradation [10]. Retention in the ER lumen per se is not
sufficient to promote degradation; several resident ER
lumen proteins such as BiP and protein disulphide iso-
merase are very stable. At present, it is unclear whether
secretory proteins subject to ER degradation, such as
unassembled immunoglobulins, are degraded within the
ER lumen, perhaps in some specialized region, or whether
they too are ultimately degraded by proteasomes in the
cytosol. If the latter proves to be the case there must be a
mechanism for protein export from the ER. Some time ago,
the yeast ER was shown to export a glycosylated tripeptide
directly into the cytosol, rather than by vesicular transport
to the Golgi complex [11]. Although a glycosylated tripep-
tide clearly falls somewhat short of a typical protein, a more
recent report has provided evidence that misfolded prepro-
a factor in the yeast ER may also be degraded in the
cytosol [12]. Significantly, it was noted that mutations in
genes encoding a chymotrypsin-like subunit of the yeast
proteasome inhibit this degradation [12].
It seems unlikely that HCMV is the only opportunist to
use ER degradation for its own advantage. Other danger-
ous invaders might parasitize putative ER export machin-
ery. For example, certain cytotoxic proteins such as ricin,
which enter mammalian cells by endocytosis, might reach
their target substrates in the cytosol by translocating from
the ER lumen [13]. If such toxins partially unfold upon
reaching the ER lumen, possibly followed by insertion
into the ER membrane, they may be exported into the
cytosol by a housekeeping system that removes unwanted
proteins from this compartment. Should this prove to be
the case, the toxins must somehow avoid proteasomal
degradation, at least to some extent, to allow refolding into
the catalytically-active conformation required to inactivate
cellular protein synthesis.
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